report result market open april compani
offer detail guidanc reset consensu expect
level regard attain despit variou challeng think
remain track achiev target outlin long-rang plan reiter
market perform increas pt
guidanc mostli match expect look achiev
januari guid cc revenu growth oper growth
compani sale growth guidanc report basi impli
revenu came street initi forecast
mis-model currenc impact revenu target
line guidanc current street forecast notabl factor affect
revenu year project full-year cyclophosphamid sale
due on-going gener competit compani also face full-
year impact relat lower sale brevibloc well lower
 in-cent hd sale two item lower growth approxim
basi point bax oper sale growth calcul exclud impact foreign
exchang gener cyclophosphamid competit includ impact
latter two item guid adjust oper margin expans basi
point forecast basi point compar
street target point headwind foreign exchang
above-ment impact cyclophosphamid brevibloc compani
underli margin expans basi point ep
project rang impli growth midpoint street
assumpt ep increas one cent sinc januari stand
forecast think bax earn guidanc like conserv
better-than-expect bottom-lin result keep compani track achiev
ep guidanc includ long-rang plan
clear headwind kept street estim check
compani expect revenu increas cc basi
oper basi compani report sale growth declin impli
total revenu figur forecast share street
sever specif item affect revenu first biggest impact brevibloc
felt estim hit account basi point
growth second heighten buy pattern iv busi creat
headwind roughli basi point growth third compani
experi anoth impact roughli basi point lower in-
center hd sale sum total headwind basi point that includ
oper sale growth guidanc target repres
pronounc quarterli impact face year result believ expect
temper particular investor satisfi in-lin
slightli better revenu result bax ep guidanc compar
forecast consensu compani estim experi
hit brevibloc impact currenc hit
cyclophosphamid project shown figur page
pleas see page report import disclosur
compani split allow baxter better focu deliv margin expans
top bottom line growth opportun longer term new baxter
hamper low singl digit top line growth trajectori lower oper
ebitda margin profil rel peer earli go clearer path forward
abl acceler top line growth better expect margin expans
opportun could bolster long-term outlook given top-lin margin profil
new baxter believ compani deserv trade premium med tech peer
current valuat keep us market perform
focus support compani
oper cash flow track grow
new tuck-in bolt-on acquisit
expect gener top-lin
gambro margin synergi deliv
improv ahead expect
om ebitda margin expans
opportun realiz sooner
pipelin opportun acquisit
contribut next five year
gambro margin synergi fail
meet key benchmark improv
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani develop medic
devic product use hospit kidney dialysi center nurs home rehabilit
center clinic medic research laboratori patient in-hom use
biopharma solut also chronic acut product offer renal
divis gener total revenu medic product sale
complet acquisit gambro ab largest acquisit histori
bolster renal busi product portfolio juli spun bioscienc
divis form baxalta acquir shire
rais price ahead result
consist stood outlook lessen residu concern
especi sinc meaning year
valuat still encourag target believ compani track
achiev instanc still expect basi point oper
margin expans next year reach low end guidanc rang
think stock continu move higher outlook solidifi investor
gain visibl pipelin meanwhil increas price target
ahead result new target appli mean forward multipl large-
cap medic devic compani ep ebitda averag result
valu reiter market perform rate time
compani report thomson eikon cowen compani
medic good gross gross total expens incom incom tax incom tax incom oper ex intang incom non-controlling inc inc oper ex-intang share estim cowen
compani report thomson eikon cowen compani
compani report cowen compani estim
year end decemb end decemb end decemb medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang oper ex-intang oper ep includ intang share cowen
compani report cowen compani estim
compani report cowen compani estim
good gross gross total expens incom incom tax incom tax incom oper ex-intang oper ex-intang oper ep includ intang restructur non-recur gain share analysisgross cowen
compani report cowen compani estim
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
